BRIEF-Immix Biopharma Accelerates Enrollment In U.S. AL Amyloidosis Trial Of NXC-201 CAR-T
ReutersJan 7, 2025 4:08 PM
Jan 7 (Reuters) - Immix Biopharma Inc IMMX.O:
IMMIX BIOPHARMA ACCELERATES ENROLLMENT IN U.S. AL AMYLOIDOSIS TRIAL OF NXC-201 CAR-T
IMMIX BIOPHARMA INC: ON TRACK FOR NEXT PROGRAM UPDATE IN Q1 2025
Source text: ID:nGNX1WJxc4
Further company coverage: IMMX.O
(((( Reuters.Briefs@thomsonreuters.com ;));))
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Related Articles
U.S. Bond Yields Soar in Trump 2.0, Time to Buy U.S. Bonds?
TradingKey - The news that the new Trump administration will trigger potential inflation is everywhere, and while the market is questioning the growth dynamics of the stock market, Wall Street is making asset allocation recommendations to buy U.S. Treasuries.TradingKey
6 hours ago
Why Did The S&P 500 And Nasdaq Composite Just Fall Over 1%?
TradingKey - The year 2025 started off on a pretty solid footing for investors with the key indices in the US – the S&P 500 Index and the tech-focused Nasdaq Composite Index – both posting gains in the first few days of trading. That followed on from some huge double-digit gains for 2023 and 2024.TradingKey
15 hours ago
Despite raging bull market in U.S. stocks, European stock gains to catch up in 2025?
TradingKey - As we look ahead to 2025, the bullishness of major Wall Street institutions on U.S. stocks is only growing. And outside of U.S. stocks, Wall Street expects European stocks may be poised for even better performance.TradingKey
18 hours ago
Here’s Why Tencent Shares Are Down 7% Today
TradingKey - Every investor in the world has had to grow accustomed to rising geopolitical tensions over the past decade between the world’s two superpowers: the US and China. Unfortunately, for many of us, those tensions have spilled over into global stock markets.TradingKey
Tue, Jan 7
